Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 4/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717432 | 0.89 | FYN (0.38) | FYNCHEK2MAP3K11MAP4K4 | |
| SCHEMBL1702596 | 0.82 | CYP3A4 (0.41) | FYN | |
| SCHEMBL2446596 | 0.78 | CYP3A4 (0.33) | — | |
| SCHEMBL1702352 | 0.78 | CYP3A4 (0.32) | — | |
| SCHEMBL1702767 | 0.75 | MAPK10 (0.41) | — | |
| SCHEMBL1703190 | 0.74 | CYP3A4 (0.41) | — | |
| SCHEMBL16152430 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL2447905 | 0.72 | MAP3K11 (0.41) | MAP3K11 | |
| SCHEMBL12302501 | 0.70 | CYP3A4 (0.39) | MAP3K11 | |
| SCHEMBL1702740 | 0.70 | ERBB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | FYN 3846/4885CHEK2 2453/4885MAP3K11 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.